Karim FIZAZI
Gustave Roussy, Cancer Campus, Grand Paris · Gustave Roussy, Villejuif · Gustave Roussy Cancer Campus, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Karim FIZAZI as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:27 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06625970 · Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of RelapseUNICANCER · recruiting · High Risk Prostate Carcinoma, Prostate Cancer · study chair
- Ph3NCT06496581 · Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)UNICANCER · recruiting · Prostate Cancer Metastatic · study chair
- Ph3NCT05874063 · Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell TumorsGustave Roussy, Cancer Campus, Grand Paris · recruiting · Germ Cell Tumor · principal investigator
- Ph3NCT04916613 · ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)UNICANCER · recruiting · Prostate Cancer Metastatic · principal investigator
- Ph1/Ph2NCT03436485 · Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerOrion Corporation, Orion Pharma · active not recruiting · Prostate Cancer Metastatic · principal investigator
- Ph2NCT03314324 · A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate CancerGustave Roussy, Cancer Campus, Grand Paris · completed · Metastatic Castrate-resistant Prostate (CRPC) Cancer · study chair
- Ph1/Ph2NCT02344017 · Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate CancerOrion Corporation, Orion Pharma · completed · Prostate Cancer · principal investigator
- Ph2NCT02115165 · A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell TumorsGustave Roussy, Cancer Campus, Grand Paris · completed · Non-seminomatous Germ-cell Tumors · study chair
- Ph3NCT02044354 · Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate CancerGustave Roussy, Cancer Campus, Grand Paris · completed · Metastatic Castration-resistant Prostate Cancer · study chair
- Ph3NCT01957436 · A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerUNICANCER · active not recruiting · Metastatic Prostate Cancer · study chair
- Ph3NCT01952223 · A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of RelapseUNICANCER · active not recruiting · Adenocarcinoma of Prostate, Progression of Prostate Cancer · principal investigator
- Ph1NCT01784757 · Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate CancerOrion Corporation, Orion Pharma · completed · Prostate Cancer · principal investigator
- Ph3NCT01540058 · Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUPGustave Roussy, Cancer Campus, Grand Paris · completed · Neoplasms, Unknown Primary · principal investigator
- Ph2NCT01429064 · Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001Orion Corporation, Orion Pharma · completed · Prostate Cancer · principal investigator
- Ph1/Ph2NCT01317641 · Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate CancerOrion Corporation, Orion Pharma · completed · Prostate Cancer · principal investigator
- Ph3NCT01083615 · A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)Achieve Life Sciences · terminated · Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer · principal investigator
- Ph3NCT00617669 · A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate CancerAstraZeneca · completed · Prostate Cancer · principal investigator
- Ph2NCT00127049 · Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell TumorsGustave Roussy, Cancer Campus, Grand Paris · unknown · Germ Cell Tumor · principal investigator
- Ph2NCT00127088 · Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer PatientsGustave Roussy, Cancer Campus, Grand Paris · suspended · Prostate Cancer · principal investigator
- Ph2NCT00126230 · Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate CancerGustave Roussy, Cancer Campus, Grand Paris · terminated · Prostate Cancer · principal investigator
- Ph3NCT00126269 · Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown PrimaryGustave Roussy, Cancer Campus, Grand Paris · unknown · Carcinoma · principal investigator
- Ph3NCT00104676 · Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell TumorsUNICANCER · completed · Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor · study chair
- Ph3NCT00055731 · Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of RelapseUNICANCER · completed · Prostate Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:27 UTC. The ranking covers the 200 most relevant of 217 PubMed records, and a shared surname and initials can bring in a namesake. All 217 on PubMed
- Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med · 20123,750 citationsRCR 102.0
- Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med · 20113,643 citationsRCR 95.7
- Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med · 20142,392 citationsRCR 70.7
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 20212,357 citationsRCR 149.5
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med · 20132,334 citationsRCR 67.7
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 20201,923 citationsRCR 83.2
- 1,866 citationsRCR 65.3
- 1,475 citationsRCR 40.9
- 1,256 citationsRCR 33.8
- 1,127 citationsRCR 30.7